Diagnosis and management of lymphoma.
The 42nd Annual Meeting of the American Society of Clinical Oncology was held in Atlanta, GA, June 2-6, 2006. Some of the presentations pertaining to the diagnosis and management of non-Hodgkin's lymphoma are summarized in this review. Principal issues in indolent lymphoma included the role of maintenance therapy, novel agents such as bendamustine and pixantrone, and updates of predictive factors. Studies in aggressive lymphomas included standard regimens, such as rituximab-based chemotherapy and radioimmunotherapy, as well as novel salvage regimens. Advances in the management of mantle cell lymphoma with radioimmunotherapy, hyper-CVAD (cyclophosphamide/vincristine/doxorubicin/dexamethasone) and emerging agents, such as bortezomib and temsirolimus, were presented.
Abbott
Brian L
BL
Lymphoma Program, University of Colorado Cancer Center, Aurora, CO 80045-0510, USA. abbottmd@gmail.com
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis* / Q000628:therapy*; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis* / Q000628:therapy*; D016399:Lymphoma, T-Cell / Q000175:diagnosis* / Q000628:therapy*; D016499:Radioimmunotherapy / Q000379:methods; D016896:Treatment Outcome
D000970:Antineoplastic Agents